138 related articles for article (PubMed ID: 37555785)
1. Endemic statistical paradoxes in epidemiologic studies distort knowledge on prostate cancer: mitigation and caution of fallacies in prostate cancer causal epidemiological studies.
Cussenot O; Fromont G; Cancel-Tassin G; Hamdy FC; Martin RM
Curr Opin Urol; 2023 Nov; 33(6):421-427. PubMed ID: 37555785
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
Botchorishvili G; Matikainen MP; Lilja H
Curr Opin Urol; 2009 May; 19(3):221-6. PubMed ID: 19318948
[TBL] [Abstract][Full Text] [Related]
4. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
5. Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening.
Wheeler DC; Szymanski KM; Black A; Nelson DE
BMC Cancer; 2011 Apr; 11():148. PubMed ID: 21510865
[TBL] [Abstract][Full Text] [Related]
6. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
[TBL] [Abstract][Full Text] [Related]
7. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era.
Platz EA; De Marzo AM; Giovannucci E
J Cell Biochem; 2004 Feb; 91(3):553-71. PubMed ID: 14755685
[TBL] [Abstract][Full Text] [Related]
9. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
10. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy.
García-Cruz E; Carrión Puig A; García-Larrosa A; Sallent A; Castañeda-Argáiz R; Piqueras M; Ribal MJ; Leibar-Tamayo A; Romero-Otero J; Alcaraz A
Scand J Urol; 2013 Aug; 47(4):282-9. PubMed ID: 23181478
[TBL] [Abstract][Full Text] [Related]
11. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen screening: pro.
Loeb S; Catalona WJ
Curr Opin Urol; 2010 May; 20(3):185-8. PubMed ID: 20224413
[TBL] [Abstract][Full Text] [Related]
13. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.
Louie KS; Seigneurin A; Cathcart P; Sasieni P
Ann Oncol; 2015 May; 26(5):848-864. PubMed ID: 25403590
[TBL] [Abstract][Full Text] [Related]
14. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer.
Ola IO; Talala K; Tammela T; Taari K; Murtola T; Kujala P; Raitanen J; Auvinen A
Int J Cancer; 2023 Feb; 152(4):672-678. PubMed ID: 36056577
[TBL] [Abstract][Full Text] [Related]
16. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
17. The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?
Schmid M; Trinh QD; Graefen M; Fisch M; Chun FK; Hansen J
World J Urol; 2014 Aug; 32(4):871-80. PubMed ID: 24825472
[TBL] [Abstract][Full Text] [Related]
18. Risk of developing prostate cancer in the future: overview of prognostic biomarkers.
Fleshner NE; Lawrentschuk N
Urology; 2009 May; 73(5 Suppl):S21-7. PubMed ID: 19375623
[TBL] [Abstract][Full Text] [Related]
19. Epidemiological study on more accurate diagnosis of prostate cancer.
Kopecký J; Navláčilová V; Janoutová J; Janout V
Cent Eur J Public Health; 2020 Mar; 28(1):65-69. PubMed ID: 32228820
[TBL] [Abstract][Full Text] [Related]
20. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]